Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12540386 | 0.98 | HTR2C (0.44) | HTR2CPNMTCD44MAOBHTR2B | |
| SCHEMBL1171436 | 0.89 | HTR2C (0.57) | HTR2CHTR2BHTR2AHTR6HTR3E | |
| SCHEMBL29935595 | 0.87 | HTR2C (0.46) | HTR2CPNMTCD44MAOBHTR2B | |
| SCHEMBL12478204 | 0.85 | PTGS2 (0.39) | SMN1; SMN2PTGS2ESR2AADAT | |
| SCHEMBL15533052 | 0.84 | OGA (0.39) | HTR2CHTR2BHTR2AS1PR1OGA | |
| SCHEMBL18131953 | 0.84 | CHRNB2 (0.42) | S1PR1POLBSMN1; SMN2 | |
| SCHEMBL15533041 | 0.83 | NOTUM (0.41) | HTR2CHTR2BS1PR1SIGMAR1PARP1 | |
| SCHEMBL16852982 | 0.82 | DRD2 (0.45) | HTR2CPNMTHTR2BHTR2AS1PR1 | |
| SCHEMBL15533393 | 0.81 | HTR3E (0.45) | HTR2CHTR2BHTR2AS1PR1HTR3E | |
| Hydrochloric Acid SCHEMBL17202420 | 0.80 | HTR3E (0.44) | HTR2CHTR2BHTR2AS1PR1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2023-08-03 | — | — | US | disclosed |
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-2847193-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-20 | — | — | US | disclosed |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| US-20140275061-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| EP-2766345-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013169964-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013055984-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2513108-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI (FR) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011080444-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080444-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | disclosed |
| EP-1305048-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | Wockhardt Limited (IN) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002009758-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | WOCKHARDT LIMITED (IN) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | GAA, GBA3, ENGASE | HTR2C 4006/4885PNMT 1443/4885CD44 2449/4885 |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | F12, TFPI, F11 | HTR2C 1391/4885PNMT 3717/4885CD44 4689/4885 |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | HTR2C 11/4885PNMT 9/4885CD44 4730/4885 |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | HTR2C 1202/4885PNMT 4018/4885CD44 4686/4885 |
| US-20140275061-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HTR2C 982/4885PNMT 2887/4885CD44 4844/4885 |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | HTR2C 11/4885PNMT 9/4885CD44 4730/4885 |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | HTR2C 982/4885PNMT 2887/4885CD44 4844/4885 |
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLI1, SHH, GLI2 | HTR2C 1579/4885PNMT 1043/4885CD44 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.